Karine Tawagi, Assistant Professor of Clinical Medicine and Fellowship Program Director at the University of Illinois Chicago, shared on X:
“PAPMET2 trial Benjamin L Maughan although closed early d/t slow enrollment, still very meaningful to show more data to support IO/TKI preferred over TKI in papillary RCC.
36 pts enrolled Higher PFS and ORR with doublet Results of STELLAR-304, SAMETA and AXIPAP are pending!”
You can also read:
LITESPARK-011 at ESMO 2026: Association Between HRQoL and Clinical Outcomes in Advanced RCC
